Want to see FLNA full AI Analyst Report?
Top Page
Filana Therapeutics
(NASDAQ:FLNA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.97
▲(8.43% Upside)
Action:Reiterated
Date:06/15/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and cash burn with declining equity/assets) and a bearish technical setup (below key moving averages with negative MACD). Valuation offers limited help due to negative earnings and no dividend, while the recent corporate event is modestly positive but not enough to offset the core risks.
Positive Factors
Low Leverage
Near-zero debt provides structural financial flexibility for a development-stage biotech. Low leverage reduces bankruptcy risk and preserves optionality to fund R&D through equity raises, partnerships, or milestone financing without large fixed interest burdens.
Negative Factors
No Revenue
A complete absence of commercial revenue means the company lacks validated product sales or recurring cash inflows. Long-term value is therefore binary and dependent on successful clinical outcomes, licensing, or partnership deals to create sustainable revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Near-zero debt provides structural financial flexibility for a development-stage biotech. Low leverage reduces bankruptcy risk and preserves optionality to fund R&D through equity raises, partnerships, or milestone financing without large fixed interest burdens.
Read all positive factors
Filana Therapeutics (FLNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$48.79M
Dividend YieldN/A
Average Volume (3M)356.28K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue GrowthN/A
EPS Growth65.77%
CountryUS
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,307,896
10 Day Avg. Volume355,122
30 Day Avg. Volume356,284
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-3.02
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.00Price Target Upside461.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Filana Therapeutics Business Overview & Revenue Model
Company Description
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational c...
How the Company Makes Money
null...
Filana Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -667.00K | -936.00K | 0.00 | -89.42M | -68.03M | 0.00 |
| EBITDA | -31.94M | -90.04M | -141.15M | -104.43M | -78.72M | -32.33M |
| Net Income | -31.95M | -90.97M | -24.34M | -97.22M | -76.25M | -32.38M |
Balance Sheet | ||||||
| Total Assets | 103.90M | 118.36M | 157.53M | 151.66M | 234.83M | 266.78M |
| Cash, Cash Equivalents and Short-Term Investments | 82.68M | 95.50M | 128.57M | 121.14M | 201.01M | 233.44M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 139.00K | 236.00K |
| Total Liabilities | 40.29M | 43.95M | 11.83M | 14.20M | 7.29M | 12.87M |
| Stockholders Equity | 63.61M | 74.40M | 145.70M | 137.47M | 227.54M | 253.91M |
Cash Flow | ||||||
| Free Cash Flow | -20.43M | -32.83M | -117.03M | -82.44M | -80.23M | -52.41M |
| Operating Cash Flow | -19.82M | -32.25M | -116.93M | -82.03M | -77.51M | -30.20M |
| Investing Cash Flow | -602.00K | -581.00K | -103.00K | -414.00K | -2.71M | -22.21M |
| Financing Cash Flow | -345.00K | -239.00K | 124.47M | 2.56M | 47.80M | 192.34M |
Filana Therapeutics Technical Analysis
Negative
0.89
Price Trends
1.17
Negative
1.37
Negative
1.96
Negative
Market Momentum
-0.06
Negative
44.93
Neutral
65.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FLNA, the sentiment is Negative. The current price of 0.89 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.17, and below the 200-day MA of 1.96, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.93 is Neutral, neither overbought nor oversold. The STOCH value of 65.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FLNA.
Filana Therapeutics Risk Analysis
Filana Therapeutics disclosed 52 risk factors in its most recent earnings report. Filana Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Filana Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $116.36M | -11.46 | -65.73% | ― | ― | 19.64% | |
49 Neutral | $179.14M | -1.52 | -194.74% | ― | 160.53% | 12.32% | |
48 Neutral | $79.62M | -3.40 | -38.41% | ― | ― | 64.57% | |
45 Neutral | $46.77M | -0.93 | -60.32% | ― | ― | 49.74% | |
44 Neutral | $48.79M | -1.16 | -58.78% | ― | ― | 65.77% | |
44 Neutral | $150.59M | -3.83 | -68.09% | ― | 56.76% | 63.33% |
* Healthcare Sector Average
FLNA
Filana Therapeutics
1.00
-1.26
-55.78%
CDXS
Codexis
1.47
-1.33
-47.50%
MCRB
Seres Therapeutics
4.87
-9.66
-66.48%
ANIX
Anixa Biosciences
3.42
0.48
16.33%
CGTX
Cognition Therapeutics
1.08
0.22
25.58%
CAMP
CAMP4 Therapeutics Corporation
4.24
2.88
211.76%
Filana Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Filana Therapeutics Shareholders Back Board, Compensation Plans
Positive
Jun 15, 2026
Filana Therapeutics held its 2026 Annual Meeting of Stockholders on June 11, 2026, with about 51% of eligible shares represented, establishing a quorum for voting. Shareholders elected three directors, Richard J. Barry, Pierre Gravier and Claude N...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.